JP2018508214A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508214A5
JP2018508214A5 JP2017546081A JP2017546081A JP2018508214A5 JP 2018508214 A5 JP2018508214 A5 JP 2018508214A5 JP 2017546081 A JP2017546081 A JP 2017546081A JP 2017546081 A JP2017546081 A JP 2017546081A JP 2018508214 A5 JP2018508214 A5 JP 2018508214A5
Authority
JP
Japan
Prior art keywords
binding molecule
acid sequence
seq
amino acid
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017546081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508214A (ja
JP6793655B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/020920 external-priority patent/WO2016141303A2/en
Publication of JP2018508214A publication Critical patent/JP2018508214A/ja
Publication of JP2018508214A5 publication Critical patent/JP2018508214A5/ja
Application granted granted Critical
Publication of JP6793655B2 publication Critical patent/JP6793655B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017546081A 2015-03-04 2016-03-04 Cd20結合分子およびその使用方法 Active JP6793655B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128284P 2015-03-04 2015-03-04
US62/128,284 2015-03-04
PCT/US2016/020920 WO2016141303A2 (en) 2015-03-04 2016-03-04 Cd20 binding molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020186950A Division JP2021036885A (ja) 2015-03-04 2020-11-10 Cd20結合分子およびその使用方法

Publications (3)

Publication Number Publication Date
JP2018508214A JP2018508214A (ja) 2018-03-29
JP2018508214A5 true JP2018508214A5 (https=) 2019-04-11
JP6793655B2 JP6793655B2 (ja) 2020-12-02

Family

ID=56849117

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017546081A Active JP6793655B2 (ja) 2015-03-04 2016-03-04 Cd20結合分子およびその使用方法
JP2020186950A Pending JP2021036885A (ja) 2015-03-04 2020-11-10 Cd20結合分子およびその使用方法
JP2023078176A Pending JP2023099206A (ja) 2015-03-04 2023-05-10 Cd20結合分子およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020186950A Pending JP2021036885A (ja) 2015-03-04 2020-11-10 Cd20結合分子およびその使用方法
JP2023078176A Pending JP2023099206A (ja) 2015-03-04 2023-05-10 Cd20結合分子およびその使用方法

Country Status (18)

Country Link
US (2) US10787520B2 (https=)
EP (2) EP3265575B1 (https=)
JP (3) JP6793655B2 (https=)
KR (4) KR102357312B1 (https=)
CN (2) CN107532188B (https=)
AU (3) AU2016226060B2 (https=)
BR (1) BR112017018941B8 (https=)
CA (1) CA2978324A1 (https=)
DK (1) DK3265575T3 (https=)
ES (1) ES2874558T3 (https=)
HU (1) HUE054642T2 (https=)
IL (2) IL297997A (https=)
NZ (1) NZ762365A (https=)
PL (1) PL3265575T3 (https=)
PT (1) PT3265575T (https=)
SG (2) SG11201707144VA (https=)
SI (1) SI3265575T1 (https=)
WO (1) WO2016141303A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6721505B2 (ja) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド 定常領域が修飾された(constant chain modified)二重特異性五価及び六価Ig−M抗体
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
JP2017512208A (ja) 2014-02-10 2017-05-18 アイジーエム バイオサイエンス, インコーポレイテッド IgA多重特異性結合分子
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
ES2919749T3 (es) 2014-06-11 2022-07-28 Molecular Templates Inc Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
MX2017010072A (es) 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
JP6979971B2 (ja) 2016-05-09 2021-12-15 アイジーエム バイオサイエンシズ インコーポレイテッド 抗pd−l1抗体
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
EP3573648B1 (en) 2017-01-25 2023-11-22 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
KR20210083260A (ko) * 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
MX2022001934A (es) 2019-08-15 2022-03-11 Igm Biosciences Inc Moleculas de union multimericas inmunoestimuladoras.
CN114616031A (zh) * 2019-09-19 2022-06-10 Igm生物科学股份有限公司 对靶标密度高的细胞的选择性增强的多聚体抗体
BR112022021392A2 (pt) 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
US20240002526A1 (en) * 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
CN112521508B (zh) * 2020-12-29 2021-08-03 郴州宾泽医学检验有限公司 一种cd20抗体及其治疗癌症的应用
JP2024508709A (ja) * 2021-02-17 2024-02-28 アイジーエム バイオサイエンシズ インコーポレイテッド 抗cd123結合分子及びその使用法
NL2030990B1 (en) * 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1
WO2024073700A2 (en) * 2022-09-30 2024-04-04 Igm Biosciences, Inc. Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies
JP2026502759A (ja) * 2023-01-06 2026-01-27 アイジーエム バイオサイエンシズ インコーポレイテッド T細胞共刺激多量体結合分子及びその使用
WO2025076144A1 (en) * 2023-10-03 2025-04-10 Atara Biotherapeutics, Inc. Bispecific cd19/cd20-targeted chimeric antigen receptors and uses thereof
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6476198B1 (en) * 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
AU740918B2 (en) * 1997-01-10 2001-11-15 Plantibodies Corporation Novel epithelial tissue targeting agent
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
CA2375912C (en) 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
AU2001257445B2 (en) 2000-04-28 2006-11-02 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
MXPA02011092A (es) 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para demostrar la regulacion del sistema inmune secretor del crecimiento de la celula de cancer que responde a la hormona esteroidea.
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-cd20 항체 및 그 융합 단백질 및 이들의 이용방법
US7282567B2 (en) 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
KR101017732B1 (ko) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-cd74 항체 및 그 이용방법
BR0309254A (pt) 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
NZ537277A (en) * 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CN101928344B (zh) * 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
EP1626992B1 (en) 2003-05-23 2010-06-02 Crucell Holland B.V. Production of recombinant igm in per.c6 cells
ATE490787T1 (de) 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CN101098889A (zh) 2004-11-05 2008-01-02 盘林京有限公司 抗体导致的细胞膜损伤
ES2665422T3 (es) 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
US8349332B2 (en) * 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
KR20080031001A (ko) * 2005-06-02 2008-04-07 아스트라제네카 아베 Cd20에 대한 항체 및 그의 용도
WO2007019223A1 (en) * 2005-08-03 2007-02-15 Therapeutic Human Polyclonals, Inc. Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101374546B (zh) * 2005-12-16 2016-03-23 Ibc医药公司 基于免疫球蛋白的多价生物活性装配体
JP2009521474A (ja) 2005-12-21 2009-06-04 メディミューン,エルエルシー EphA2BiTE分子およびその使用
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
EP2087111A2 (en) 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
WO2008135963A2 (en) * 2007-05-02 2008-11-13 Hemogem Inc. Fibrinogen for treatment of bleeding in trauma and platelet disorders
CN201229536Y (zh) 2008-07-03 2009-04-29 鸿富锦精密工业(深圳)有限公司 电脑机箱
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
AU2011318567B2 (en) 2010-10-19 2017-02-09 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
TWI606064B (zh) 2012-02-08 2017-11-21 Igm生物科技公司 細胞死亡誘導分子(cdim)結合蛋白類及彼等之用途
EP3427747A1 (en) * 2012-04-05 2019-01-16 Gottfried Himmler Secretory immunoglobulin complex
EP3305323B1 (en) 2012-04-17 2021-02-17 Mayo Foundation for Medical Education and Research Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
WO2013188870A2 (en) 2012-06-15 2013-12-19 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
CN104684928A (zh) * 2012-08-02 2015-06-03 Jn生物科学有限责任公司 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10066238B2 (en) 2013-02-11 2018-09-04 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
JP6721505B2 (ja) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド 定常領域が修飾された(constant chain modified)二重特異性五価及び六価Ig−M抗体
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
SG10201806025TA (en) 2014-01-16 2018-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
JP2017512208A (ja) 2014-02-10 2017-05-18 アイジーエム バイオサイエンス, インコーポレイテッド IgA多重特異性結合分子
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
FI3319936T3 (fi) 2015-07-12 2026-03-12 Hangzhou Dac Biotech Co Ltd Silloituslinkkereitä soluun sitoutuvien molekyylien konjugoimiseksi
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
JP6979971B2 (ja) 2016-05-09 2021-12-15 アイジーエム バイオサイエンシズ インコーポレイテッド 抗pd−l1抗体
AU2017300647A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric GITR binding molecules and uses thereof
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
EP3487298A4 (en) 2016-07-20 2020-03-11 IGM Biosciences, Inc. MULTIMERE CD137 / 4-1BB-BINDING MOLECULES AND USES THEREOF
JP2019530640A (ja) 2016-07-20 2019-10-24 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ox40結合分子及びその使用
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
AU2019224136A1 (en) 2018-02-26 2020-09-10 Igm Biosciences, Inc. Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
KR20210083260A (ko) 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자

Similar Documents

Publication Publication Date Title
JP2018508214A5 (https=)
JP7624484B2 (ja) 新規抗pd-l1抗体
JP7499813B2 (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
US20240343810A1 (en) Multispecific antibodies for immuno-oncology
JP7461950B2 (ja) Cd3抗体およびその医薬用途
CN113874399B (zh) 抗ror1/抗cd3双特异性结合分子
JP6702893B2 (ja) 多重特異的抗原結合タンパク質
JP2021058186A (ja) Ox40に対する抗体およびその使用
KR20200079511A (ko) Cd47 항원-결합 분자
US20260049143A1 (en) Multispecific antibody with combination therapy for immuno-oncology
BR112021009325A2 (pt) Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
JP2022513053A (ja) B7-H3のIgVドメインに対するモノクローナル抗体及びその使用
JP2019532619A5 (https=)
KR20180095086A (ko) 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
HK1215035A1 (zh) 人源化抗cd134(ox40)抗體及其應用
US20230192845A1 (en) Cd96-binding agents as immunomodulators
JP7836033B2 (ja) Gprc5d抗体及びその応用
WO2020114479A1 (zh) 多特异性蛋白分子
JP2020515277A5 (https=)
CN119948063A (zh) 结合egfr和b7-h3的双特异性抗体
CN108138172A (zh) 抗体
CA3228641A1 (en) Fap/cd40 binding molecule and medicinal use thereof
CN116234572A (zh) 治疗性SIRPα抗体
CN112236456B (zh) 新型双特异性pd-1/lag-3抗体分子
CN120958026A (zh) Fap/4-1bb/cd40结合分子及其医药用途